BeStock  
Stocks › Biotechnology › AKTS

Aktis Oncology AKTS

US equityMarket cap rank #3226Biotechnology
$16.15 −$0.25 (-1.52%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.46 +1.92%
Open$16.32
Prev close$16.40
Day range$16.00 – $16.74
Volume375.0K
Market cap$901.14M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership92.4%+2.08 pts vs. prior quarter
Institutions holding147+5 vs. prior quarter
Insider trades (recent)7 buys / 5 sellsNet buying
Short interest7.96% of floatDays to cover 16.0 · as of 30 Oct 2026
Short-sale volume share29.2%5-day average of daily volume

Short-sale volume as % of daily volume

10%20%31%41%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.64M (5 inflow days, 15 outflow days).

Net flow by order size, last 20 sessions

−$1.0MSuper−$598.0KBig−$228.9KMid+$8,870Small

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 46.7% of shares outstanding.

Largest holders

  • Eli Lilly and Company11.41%
  • EcoR1 Capital, LLC10.56%
  • Vida Ventures Advisors, LLC10.48%
  • MPM BioImpact LLC8.69%
  • CHI Advisors LLC5.52%
  • T. Rowe Price Group, Inc.5.06%
  • BlackRock5.00%
  • Blue Owl Credit Private Fund Advisors LLC4.37%

By investor type

  • VC/PE Fund30.83%
  • Mutual Fund25.85%
  • Hedge Fund23.31%
  • Public Company11.95%
  • Individual/Insider0.46%
  • Family Office/Trust0.20%
  • Private Company0.11%
  • Insurance Company0.08%

Reported short interest has risen from 6.20% to 7.96% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
State Street Global Advisors Mutual Fund 2026/Q3 +566,470 1.9%
BlackRock Mutual Fund 2026/Q3 +502,387 5.0%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +363,850 2.1%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +169,690 1.2%
TD Asset Management Mutual Fund 2026/Q3 +97,592 0.4%
Mirador Capital Partners, LP Mutual Fund 2026/Q3 +93,434 0.2%
BNP Paribas Financial Markets SNC Private Company 2026/Q3 +67,536 0.1%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +53,166 0.4%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +28,933 0.2%
Curran Financial Partners, LLC Mutual Fund 2026/Q3 +52,588 0.1%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +41,719 0.1%
TCG Crossover Management, LLC VC/PE Fund 2026/Q3 +696,560 1.3%
BlackRock Mutual Fund 2026/Q3 +166,231 4.1%
Barclays PLC Public Company 2026/Q3 +146,282 0.3%
Renaissance Technologies Corp. Hedge Fund 2026/Q3 +95,400 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
22 Sep 2026 Akos Czibere Chief Medical Officer Derivative Exercise and Sale -12,500 $21.03 –
19 Jul 2026 Ken Herrmann Chair of Scientific Advisory Board & Independent Director Derivative Exercise and Sale -4,856 $24.56 –
16 Jul 2026 Ken Herrmann Chair of Scientific Advisory Board & Independent Director Derivative Exercise and Sale -3,065 $25.21 –
7 Jul 2026 Shulamit Ron-Bigger Chief Operating Officer Derivative Exercise and Sale -50,000 $28.75 –
7 Jul 2026 Akos Czibere Chief Medical Officer Derivative Exercise and Sale -50,000 $28.71 –
11 Jan 2026 MPM BioImpact LLC Private Acquisition +1,112,777 $18.00 10,260,064
11 Jan 2026 MPM BioImpact LLC Derivative Exercise and Retained +8,208,187 – 10,260,064
11 Jan 2026 Eli Lilly and Company Initial Statement of Beneficial +0 – 6,344,114
11 Jan 2026 Lloyd Segal Independent Director Derivative Exercise and Retained +19,631 – 19,631
11 Jan 2026 EcoR1 Capital, LLC Private Acquisition +2,222,222 $18.00 4,824,469
11 Jan 2026 EcoR1 Capital, LLC Derivative Exercise and Retained +2,602,247 – 4,824,469
11 Jan 2026 Vida Ventures Advisors, LLC Private Acquisition +835,000 $18.00 5,829,212
11 Jan 2026 Vida Ventures Advisors, LLC Derivative Exercise and Retained +4,994,212 – 5,829,212
7 Jan 2026 MPM BioImpact LLC Initial Statement of Beneficial +0 – 597,393
7 Jan 2026 Todd Foley Chairperson Initial Statement of Beneficial +0 – 37,866
7 Jan 2026 Helen Kim Former Independent Director Initial Statement of Beneficial +0 – 37,866
7 Jan 2026 Michael Sherman Independent Director Initial Statement of Beneficial +0 – 93,846
7 Jan 2026 Lloyd Segal Independent Director Initial Statement of Beneficial +0 – 6,489
7 Jan 2026 Mary Thistle Independent Director Initial Statement of Beneficial +0 – 93,846
7 Jan 2026 Matthew Roden Chief Executive Officer Initial Statement of Beneficial +0 – 2,149,409

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 4,425,903 8.0% 16.0
15 Oct 2026 4,313,744 7.8% 11.3
30 Sep 2026 4,715,294 8.5% 7.3
15 Sep 2026 3,252,475 5.8% 11.5
31 Aug 2026 3,175,040 5.7% 10.4
14 Aug 2026 3,447,126 6.2% 15.0

Discussion

No comments yet — be the first to weigh in on AKTS.

Sign in to join the discussion.

Scroll to Top